DNA TOPOISOMERASES & LATE CELL CYCLE CHECKPOINTS

DNA拓扑异构酶

• 批准号: 6298020
• 负责人: PAUL J SMITH
• 金额: $ 0.12万
• 依托单位: UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-30 至 1999-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6298020
• 关键词: biomedical resource; human tissue; nucleic acids; proteins; technology /technique

The bis(2,6-dioxopiperazine), ICRF-193, is potent non-DNA damaging inhibitor of the decantenation activity of topoisomerase II. The mechanism of inhibition is being interpreted in terms of an ATP-modulated protein-clamp model. ICRF-193 inhibits cell division but allows cell cycle traverse and progression to polyploidy with a delay at the G2 checkpoint. We will use conventional FCM methods to examine cell cycle regulation in conjunction with the various cyclins, including A and B1 and fluorescence lifetime analysis will be performed on cellular-bound ICRF-123 to analyze its interaction with chromatin.

BIS（2,6-二氧哌嗪），ICRF-193是有效的非DNA损害 拓扑异构酶II的脱酰化活性的抑制剂。 这 抑制机制正在解释 ATP调节的蛋白夹模型。 ICRF-193抑制细胞分裂 但是可以用A进行细胞周期遍历并进展到多倍体 在G2检查点上延迟。 我们将使用常规的FCM方法来 检查与各种细胞周期蛋白结合的细胞周期调节， 包括A和B1以及荧光寿命分析将是 在蜂窝结合的ICRF-123上进行，以分析其与 染色质。